🚀 VC round data is live in beta, check it out!
Gilead Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gilead Sciences and similar public comparables like Novo Nordisk, Amgen, Pfizer, Bristol-Myers Squibb and more.
Gilead Sciences Overview
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Founded
1987
HQ
Employees
17.0K
Website
Sectors
Financials (LTM)
EV
$202B
Gilead Sciences Financials
Gilead Sciences reported last 12-month revenue of $30B and EBITDA of $16B.
In the same LTM period, Gilead Sciences generated $26B in gross profit, $16B in EBITDA, and $10B in net income.
Revenue (LTM)
Gilead Sciences P&L
In the most recent fiscal year, Gilead Sciences reported revenue of $29B and EBITDA of $16B.
Gilead Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $30B | XXX | $29B | XXX | XXX | XXX |
| Gross Profit | $26B | XXX | $23B | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $16B | XXX | $16B | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 54% | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | 45% | XXX | XXX | XXX |
| Net Profit | $10B | XXX | $10B | XXX | XXX | XXX |
| Net Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| Net Debt | — | — | $17B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gilead Sciences Stock Performance
Gilead Sciences has current market cap of $186B, and enterprise value of $202B.
Market Cap Evolution
Gilead Sciences' stock price is $150.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $202B | $186B | 0.0% | XXX | XXX | XXX | $8.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGilead Sciences Valuation Multiples
Gilead Sciences trades at 6.8x EV/Revenue multiple, and 12.8x EV/EBITDA.
EV / Revenue (LTM)
Gilead Sciences Financial Valuation Multiples
As of March 21, 2026, Gilead Sciences has market cap of $186B and EV of $202B.
Equity research analysts estimate Gilead Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gilead Sciences has a P/E ratio of 18.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $186B | XXX | $186B | XXX | XXX | XXX |
| EV (current) | $202B | XXX | $202B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 12.8x | XXX | 12.7x | XXX | XXX | XXX |
| EV/EBIT | 15.0x | XXX | 15.3x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | 8.7x | XXX | XXX | XXX |
| P/E | 18.0x | XXX | 18.2x | XXX | XXX | XXX |
| EV/FCF | 18.8x | XXX | 19.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gilead Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gilead Sciences Margins & Growth Rates
Gilead Sciences' revenue in the last 12 month grew by 3%.
Gilead Sciences' revenue per employee in the last FY averaged $1.7M.
Gilead Sciences' rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gilead Sciences' rule of X is 62% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Gilead Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | (2%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 57% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gilead Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Novo Nordisk | XXX | XXX | XXX | XXX | XXX | XXX |
| Amgen | XXX | XXX | XXX | XXX | XXX | XXX |
| Pfizer | XXX | XXX | XXX | XXX | XXX | XXX |
| Bristol-Myers Squibb | XXX | XXX | XXX | XXX | XXX | XXX |
| Vertex Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gilead Sciences M&A Activity
Gilead Sciences acquired XXX companies to date.
Last acquisition by Gilead Sciences was on XXXXXXXX, XXXXX. Gilead Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gilead Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGilead Sciences Investment Activity
Gilead Sciences invested in XXX companies to date.
Gilead Sciences made its latest investment on XXXXXXXX, XXXXX. Gilead Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gilead Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gilead Sciences
| When was Gilead Sciences founded? | Gilead Sciences was founded in 1987. |
| Where is Gilead Sciences headquartered? | Gilead Sciences is headquartered in United States. |
| How many employees does Gilead Sciences have? | As of today, Gilead Sciences has over 17K employees. |
| Who is the CEO of Gilead Sciences? | Gilead Sciences' CEO is Daniel P. O'Day. |
| Is Gilead Sciences publicly listed? | Yes, Gilead Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Gilead Sciences? | Gilead Sciences trades under GILD ticker. |
| When did Gilead Sciences go public? | Gilead Sciences went public in 1992. |
| Who are competitors of Gilead Sciences? | Gilead Sciences main competitors are Novo Nordisk, Amgen, Pfizer, Bristol-Myers Squibb. |
| What is the current market cap of Gilead Sciences? | Gilead Sciences' current market cap is $186B. |
| What is the current revenue of Gilead Sciences? | Gilead Sciences' last 12 months revenue is $30B. |
| What is the current revenue growth of Gilead Sciences? | Gilead Sciences revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Gilead Sciences? | Current revenue multiple of Gilead Sciences is 6.8x. |
| Is Gilead Sciences profitable? | Yes, Gilead Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gilead Sciences? | Gilead Sciences' last 12 months EBITDA is $16B. |
| What is Gilead Sciences' EBITDA margin? | Gilead Sciences' last 12 months EBITDA margin is 53%. |
| What is the current EV/EBITDA multiple of Gilead Sciences? | Current EBITDA multiple of Gilead Sciences is 12.8x. |
| What is the current FCF of Gilead Sciences? | Gilead Sciences' last 12 months FCF is $11B. |
| What is Gilead Sciences' FCF margin? | Gilead Sciences' last 12 months FCF margin is 36%. |
| What is the current EV/FCF multiple of Gilead Sciences? | Current FCF multiple of Gilead Sciences is 18.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.